For pharma and healthcare professionals

A better understanding of the patient. Better support.

  • 50% of patients with chronic conditions such as hypertension, diabetes or glaucoma do not follow their treatment (Frontiers in Pharmacology, 2025)
  • Gratiago bridges the gap between the consultation and the dose
  • Actionable behavioural data, not self-reported
  • First validated randomised study in real-world clinical conditions
Schedule a demo
Two value propositions

Understand better. Support better.

For the pharmaceutical company

Understand the patient better.

Real-world behavioural data, not self-reported.
An unprecedented view of the patient experience between consultations.
A strategic steering tool for medical teams and the market access departments of pharmaceutical companies.
In practice
  • Daily data by condition
  • Aggregated, pseudonymised adherence indicators
  • Personalised quarterly reports
  • GDPR-compliant architecture · pseudonymised data
For the healthcare professional

Support the patient better.

A personalised health companion, by the patient's side every day.
  • One that prepares consultations better.
  • One that maintains the connection when the patient does not dare to bother their doctor.
  • One that strengthens day-to-day support without adding to the clinical workload.
In practice
  • Spotting drops in engagement
  • Daily behavioural support
  • No additional workload for the practitioner
Designed around the doctor

In support of the doctor, never in their place.

Gratiago acts only within the framework validated by the treating physician. The tool makes no diagnosis, issues no medical recommendation, and never substitutes for the consultation. It supports the patient day to day, prepares consultations, and strengthens the care relationship, without adding to the clinical workload.

GRACE-001 study · Results available

Results measured
in real-world conditions.

Adherence
76.8%
Mean adherence rate achieved with Gratiago over 3 months — objective measure via connected device.
Difference
+6.2pts
Advantage vs reminder-only app — peak at +9.2 pts in the 2nd month.
Retention
~70%
Of study participants continued using Gratiago spontaneously after the study ended.
Satisfaction
4.1/5
Satisfaction and ease of use score — average age 63.
First randomised single-site study in real-world clinical conditions. Ethics approval from the Comité d'Éthique Hospitalo-Facultaire UCLouvain / Saint-Luc · ref. B4032025000007.
Business model

A direct impact for our partners.

By improving treatment adherence in a given market, Gratiago delivers better health outcomes for patients and actionable real-world evidence (RWE) for the partner company. The value model is covered in a demo.
Model 01

Pharma licence

Access to the platform for a defined condition and territory. Partner branding within the patient app.

Model 02

Data & reports

Aggregated and pseudonymised behavioural data, personalised by condition and patient profile. Quarterly reports and dashboard access.

Demo & contact

Schedule a demo.

15 minutes, as a first conversation. A walkthrough of the platform, a look at GRACE-001 and a discussion of your specific use case.

Book a slot